karennma
8,057 posts
msg #129215
- Ignore karennma |
6/17/2016 10:09:24 AM
L GUSH 75.57
|
johnpaulca
12,036 posts
msg #129216
- Ignore johnpaulca |
6/17/2016 10:09:38 AM
same...I don't trade pharma's
ALXN...for intraday trade it needs to close above 125.94, you will notice some resistance here.
|
karennma
8,057 posts
msg #129217
- Ignore karennma |
6/17/2016 10:21:15 AM
karennma
6,224 posts
msg #129215
- Edit message 6/17/2016 10:09:24 AM
L GUSH 75.57
================
$76.75
Up a dollah
Will try for $2. (greed)
|
karennma
8,057 posts
msg #129220
- Ignore karennma |
6/17/2016 10:31:31 AM
GUSH - going down. well, *'d that up.
|
johnpaulca
12,036 posts
msg #129222
- Ignore johnpaulca |
6/17/2016 12:18:00 PM
johnpaulca
9,838 posts
msg #129213
- Edit message 6/17/2016 10:02:09 AM
karennma
6,222 posts
msg #129208
- Ignore karennma 6/17/2016 9:45:16 AM
Hey JP,
ALXN - where's the bottom?
*****************************************************************
intraday.......look for buyers at $124.80
**************************************************************
low $124.80...how's that for a call (:
|
graftonian
1,089 posts
msg #129223
- Ignore graftonian
modified |
6/17/2016 12:51:49 PM
Karen, have you seen this:
NEW YORK, June 8, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. ("Alexion" or "the Company") (NASDAQ: ALXN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
This investigation concerns whether Alexion and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On June 6, 2016, post-market, Alexion stated that the Company's treatment for the neuromuscular disease myasthenia gravis, called Soliris, was unsuccessful in meeting its primary goal in a final-stage trial. Patients taking the drug in a 26 week of treatments Phase 3 clinical study, did not report significant changes in the daily activities they could perform when compared to those on a placebo. Following this news, Alexion dropped $16.86 per share, or 10.88%, to close at $138.13 on June 7, 2016.
Plus, some insider trading around the first of the month
|
karennma
8,057 posts
msg #129225
- Ignore karennma |
6/17/2016 1:14:47 PM
@ graftonian,
No, I didn't hear the news.
THANK YOU!
Normally, I don't trade pharma (because drugs are news driven), but when I looked @ the chart, the price was awfully tempting. Just had a memory lapse and a small case of the greedies.
I tried adding "not medical" to my filters this morning, so I don't make that mistake again, but it didn't work.
|
graftonian
1,089 posts
msg #129226
- Ignore graftonian |
6/17/2016 1:23:14 PM
Sorry but I've always been a techno-geek. My squiggly lines say 2 to 4 days before any substantial upward movement, But, what do I know.
|
johnpaulca
12,036 posts
msg #129227
- Ignore johnpaulca |
6/17/2016 2:30:21 PM
UWTI....just hit my price target $33.52....done for the day....not holding over the weekend.
|
pthomas215
1,251 posts
msg #129228
- Ignore pthomas215 |
6/17/2016 9:06:22 PM
ALXN: RSI dipped below 20 with macd not bullish and cci 10 and 61 not sending buy signals yet.
|